Gourdy, Pierre http://orcid.org/0000-0002-5362-3813
Darmon, Patrice http://orcid.org/0000-0003-1726-2296
Borget, Isabelle http://orcid.org/0000-0002-6295-6361
Emery, Corinne http://orcid.org/0000-0002-7333-0567
Bureau, Isabelle http://orcid.org/0000-0001-6879-6357
Detournay, Bruno http://orcid.org/0000-0001-7843-4608
Bahloul, Amar http://orcid.org/0000-0003-4548-5059
Allali, Noemie http://orcid.org/0009-0008-6338-903X
Mahieu, Aymeric
Penfornis, Alfred http://orcid.org/0000-0002-9635-7674
Funding for this research was provided by:
Sanofi France (2021243)
Article History
Received: 1 February 2024
Accepted: 25 March 2024
First Online: 20 April 2024
Declarations
:
: Pierre Gourdy declares that he has received occasional fees, on a personal or institutional basis, for activities as a speaker, scientific advisor or clinical researcher, from the following companies: Abbott, Abbvie, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Intercept, LVL Médical, Merck Sharp & Dohme, Mundipharma, Organon, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier. Patrice Darmon received personal compensation for his contribution to clinical trials, scientific work, consultancy work, conferences or symposia) from Abbott, AstraZeneca, Menarini, Merck Sharp & Dohme, Mundipharma, Novo Nordisk, Sanofi, Eli Lilly, Bayer, Boehringer Ingelheim, Bastide Médical, LVL Médical. Isabelle Borget has no conflict of interest to declare. Corinne Emery and Isabelle Bureau are employed by CEMKA, a consulting team specializing in health economics, epidemiology, and outcomes research. Bruno Detournay declares that he has received fees for one-off services (scientific work, consultancy, conferences or symposia) for the following companies Cemka, Boehringer Ingelheim, Janssen, Merck Sharp & Dohme, Novo Nordisk, Sanofi, Pfizer, Eli Lilly, Cerba expert, IPSOS, Lumanity, AstraZeneca, Tillots Pharma. Bruno Detournay is an Editorial Board member of <i>Diabetes Therapy</i> and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Amar Bahloul and Noemie Allali, and Aymeric Mahieu are employed by SANOFI Winthrop Industrie, France. Alfred Penfornis declares having received fees for occasional interventions (clinical trials, scientific work, advisory activity, conferences, or symposiums) from the companies Abbott, Amgen, AstraZeneca, Dexcom, Diabeloop, Johnson & Johnson, Insulet, Isis, Merck Sharp & Dohme, Medtronic, Medtrum, Novo Nordisk, Sanofi, Eli Lilly, Ypsomed.
: This study was registered on the Health Data Hub website (T58549122021092). In accordance with current regulations, the study protocol was submitted to the committee for research, studies, and evaluations in the field of health (Comité d’Expertise pour les Recherches, les Etudes et les Evaluations dans le domaine de la Santé [CEREES]) for approval and was authorized by the French data protection authority (Commission Nationale de l’Informatique et des Libertés [CNIL], [CNIL authorization number MR: 921407).